Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer

BackgroundProstate cancer represents a major health concern worldwide, with the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and locally advanced prostate cancer posing a particular challenge. Rezvilutamide, a new androgen receptor antagonist from China, has shown early promise;...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Chunlei Zhang, Jie Ren, Yindong Kang, Dehui Chang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-03-01
coleção:	Frontiers in Oncology
Assuntos:	prostate cancer rezvilutamide metastatic hormone-sensitive prostate cancer (mHSPC) androgen deprivation therapy (ADT) genetic testing
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1374039/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!